Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 5751-5760 Newer>

Chemistry World July 10, 2009 Sarah Houlton	Branded drugs' competition-free days numbered Authorities in the US and Europe are to look carefully at the tactics pharmaceutical firms use to delay competition from generic versions of their branded drugs.
The Motley Fool July 10, 2009 Brian Orelli	Is the News Good or Bad? Who Cares! Sell! A trial comparing Merck's and Schering-Plough's cholesterol drug Zetia to Abbott Labs' Niaspan was ended early, causing a sell-off of Merck stock.
The Motley Fool July 10, 2009 Brian Orelli	Vertex Pulls a Wimpy After four follow-on stock offerings in the last three years, Vertex Pharmaceuticals finally has a plan to raise some cash that won't dilute its shareholders.
The Motley Fool July 9, 2009 Brian Orelli	Yes! It Can Handle the Pressure Rigel Pharmaceuticals' latest tests show that the side effects from its rheumatoid arthritis drug candidate R788 are manageable.
The Motley Fool July 8, 2009 Brian Orelli	Amgen Closes In on a Home Run Amgen already had a ball flying high above the outfield in its osteoporosis treatment, denosumab, but yesterday's clinical trial results were the wind that could push it out of the park.
The Motley Fool July 7, 2009 Brian Orelli	Glaxo Missed the Boat The HPV vaccine market is declining before Glaxo can hop aboard.
The Motley Fool July 6, 2009 Brian Orelli	Lilly Shows Us How It's Done The company announces that the Food and Drug Administration had expanded the approval of its cancer drug, Alimta, to include maintenance therapy for nonsquamous, non-small cell lung cancer.
PHONE+ July 2, 2009	Case Study: SRSsoft Provides Customer Service at Optimum Speed SRSsoft integrates Optimum Lightpath's Ethernet-based communications solutions to maintain it's fast response time despite it's increasing number of clients.
The Motley Fool July 2, 2009 Robert Steyer	At Last, a Heartening Drug Approval French drug giant sanofi-aventis gets FDA approval for a drug to treat an erratic heartbeat.
The Motley Fool July 2, 2009 Brian Orelli	Squeezing Blood From a Half-Dollar Johnson & Johnson is investing $1 billion in Elan in exchange for an 18.4% stake in the company.
<Older 5751-5760 Newer> Return to current articles.